Sanofi Terminates Licensing Agreement for Pompe Disease Drug Amid FTC Antitrust Lawsuit

The decision follows FTC's objection to the deal, arguing it would maintain Sanofi's monopoly over treatments for the rare genetic disorder.

Sanofi SA has terminated its licensing agreement for Maze Therapeutics Inc.'s treatment for Pompe disease following a lawsuit by the Federal Trade Commission (FTC).
The FTC sued to block the deal, arguing that the $755 million agreement would maintain Sanofi's monopoly over treatments for Pompe disease.
Sanofi currently sells two FDA-approved treatments for Pompe disease, which are administered via lengthy, biweekly intravenous infusions and cost hundreds of thousands of dollars for an annual course of treatment.
Maze's drug, MZE001, is an oral tablet taken twice daily and has completed Phase 1 development. It is expected to significantly reduce patients' treatment burden.
Sanofi decided to terminate the agreement due to the delay associated with a long litigation, stating it would not be in the best interests of patients to contest this litigation.